Sec Form 3 Filing - GordonMD Global Investments LP @ Pyxis Oncology, Inc. - 2026-06-30

FORM 3 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person GordonMD Global Investments LP 2. Issuer Name and Ticker or Trading Symbol Pyxis Oncology, Inc. [ PYXS] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) 9460 WILSHIRE BLVD, SUITE 420 3. Date of Earliest Transaction (MM/DD/YY) 06/30/2026 (Street) BEVERELY HILLS, CA90212 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) _____ Form filed by One Reporting Person __ X __ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock, par value $0.001 per share 10,024,909 I See footnote ( 1 )

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Common Stock Purchase Warrant $ 3.289 ( 3 ) ( 2 ) 07/02/2029 Common Stock, par value $0.001 per share 4,900,039 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other GordonMD Global Investments LP 9460 WILSHIRE BLVD SUITE 420 BEVERELY HILLS, CA90212 X GordonMD Long Biased Master Fund LP 9460 WILSHIRE BLVD SUITE 420 BEVERLY HILLS, CA90212 X GordonMD Long Biased GP LLC 9460 WILSHIRE BLVD SUITE 420 BEVERLY HILLS, CA90212 X Gordon Craig D 9460 WILSHIRE BLVD SUITE 420 BEVERLY HILLS, CA90212 X Signatures GordonMD Global Investments LP, By: GordonMD Global Investments GP LLC, /s/ Craig D. Gordon, Managing Member 07/10/2026 Signature of Reporting Person Date GordonMD Long Biased Master Fund LP, By: GordonMD Long Biased GP LLC, /s/ Craig D. Gordon, Managing Member 07/10/2026 Signature of Reporting Person Date GordonMD Long Biased GP LLC, /s/ Craig D. Gordon, Managing Member 07/10/2026 Signature of Reporting Person Date Craig D. Gordon, /s/ Craig D. Gordon 07/10/2026 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The securities to which this filing relates are held directly by GordonMD Long Biased Master Fund LP (the "Master Fund") to which GordonMD Global Investments LP (the "Investment Manager") serves as investment manager. Craig D. Gordon ("Mr. Gordon") is the managing member of GordonMD Long Biased GP LLC (the "GP"), the general partner of the Master Fund. Each of the Master Fund, the GP and Mr. Gordon disclaims beneficial ownership of the securities to which this filing relates for purposes of Section 16 of the Securities and Exchange Act of 1934, as amended, except to the extent of his or its pecuniary interest therein, if any. ( 2 )The Common Stock Purchase Warrant is exercisable on or after the earlier of (i) the date on which the Issuer first publicly discloses clinical data from its micvotabart pelidotin (MICVO) Phase 1 monotherapy study in 2L+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) and (ii) October 1, 2026. ( 3 )Exercise price of $3.289, subject to adjustments as set forth in the Common Stock Purchase Warrant.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.